SEARCH

SEARCH BY CITATION

References

  • 1
    Hartl FU . Molecular chaperones in cellular protein folding. Nature 1996; 13: 5719.
  • 2
    Pratt WB , Toft DO . Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med 2003; 228: 11133.
  • 3
    Blagosklonny MV . Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukaemia 2002; 16: 45562.
  • 4
    Wegele H , Müller L , Buchner J . Hsp70 and Hsp90 – a relay team for protein folding. Rev Physiol Biochem Pharmacol 2004; 151: 144.
  • 5
    Pearl LH , Prodromou C . Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 2006; 75: 27194.
  • 6
    Zhou P , Fernandes N , Dodge IL et al. ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem 2003; 278: 1382937.
  • 7
    McDonough H , Patterson C . CHIP: a link between the chaperone and proteasome systems. Cell Stress Chaperones 2003; 8: 3038.
  • 8
    Maloney A , Clarke PA , Workman P . Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspective. Curr Cancer Drug Targets 2003; 3: 33141.
  • 9
    Solit DB , Rosen N . Hsp90: a novel target for cancer therapy. Curr Top Med Chem 2006; 6: 120514.
  • 10
    Powers MV , Workman P . Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006; 13(Suppl 1): S12535.
  • 11
    Grbovic OM , Basso AD , Sawai A et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 2006; 103: 5762.
  • 12
    da Rocha DS , Friedlos F , Light Y , Springer C , Workman P , Marais R . Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2005; 65: 1068691.
  • 13
    Gorre ME , Ellwood-Yen K , Chiosis G , Rosen N , Sawyers CL . BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002; 100: 30414.
  • 14
    Shimamura T , Lowell AM , Engleman JA , Shapiro GI . Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperoneand are destabilized following exposure to geldanamycins. Cancer Res 2005; 65: 64018.
  • 15
    Sawai A , Chandarlapaty S , Greulich H et al. Inhibition of HSP90 down-regulates mutant epidermal growth factor receptor (EGFR) and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 2008; 68: 58996.
  • 16
    Kobayashi N , Toyooka S , Soh J et al. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer 2011; 75: 1616.
  • 17
    Banerji U , Walton M , Raynaud F et al. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005; 11: 702332.
  • 18
    Zhang H , Chung D , Yang YC et al. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 2006; 5: 125664.
  • 19
    Eiseman JL , Lan J , Lagattuta TF et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 2005; 55: 2132.
  • 20
    Chandarlapaty S , Sawai A , Ye Q et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 2008; 14: 2408.
  • 21
    Eccles SA , Massey A , Raynaud FI et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008; 68: 285060.
  • 22
    Bao R , Lai CJ , Qu H et al. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res 2009; 15: 404657.
  • 23
    Kamal A , Thao L , Sensintaffar J et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425: 40710.
  • 24
    Zhang H , Ching Y , Zhang L et al. Dimeric ansamycins- A new class of antitumor Hsp90 modulators with prolonged inhibitory activity. Int J Cancer 2006; 120: 91826.
  • 25
    Kefford R , Millward P , Herset B et al. Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (HSP90) inhibtior in patients with metastatic melanoma. J Clin Oncol 2007; 25: 18s; abstr 8558.
  • 26
    Modi S , Stopeck AT , Gordon MS et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007; 25: 54107.
  • 27
    Sequiist LV , Gettinger S , Natale R et al. A Phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refactory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR status. J Clin Oncol 2009; 27: 15s; abstr 8073.
  • 28
    Sharp SY , Prodromou C , Boxall K et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther 2007; 6: 1198211.
  • 29
    Kim YS , Alarcon SV , Lee S et al. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 2009; 9: 147992.
  • 30
    Jensen MR , Schoepfer J , Radimerski T et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008; 10: R33.
  • 31
    Lundgren K , Zhang H , Brekken J et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 2009; 8: 9219.
  • 32
    Woodhead AJ , Angove H , Carr MG et al. Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design. J Med Chem 2010; 53: 594255.
  • 33
    Maroney AC , Marugan JJ , Mezzasalma TM et al. Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives. Biochemistry 2006; 45: 567885.
  • 34
    Curry J , Angove H , Fazal L et al. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283. Cell Cycle 2009; 8: 19219.
  • 35
    Workman P , Aboagye EO , Balkwill F et al. An ad hoc committee of the National Cancer Research Institute Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010; 102: 155577.
  • 36
    Hollands C . The Animals (Scientific Procedures) Act 1986. Lancet 1986; 328: 323.
  • 37
    Goydos JS , Brumfield AM , Frezza E , Booth A , Lotze MT , Carty SE . Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 1998; 227: 398404.
  • 38
    Isomoto H . Epigenetic alterations in cholangiocarcinoma-sustained IL-6/STAT3 signaling in cholangio- carcinoma due to SOCS3 epigenetic silencing. Digestion 2009; 79(Suppl 1): 28.
  • 39
    Isomoto H , Kobayashi S , Werneburg NW et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005; 42: 132938.
  • 40
    Scheithauer W . Review of Gemcitabine in billary tract carcinoma. Semin Oncol 2002; 6: 405.
  • 41
    Cassier PA , Thevenet C , Walter T et al. Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma. Eur J Gastroenterol Hepatol 2010; 22: 11117.
  • 42
    Gores GJ . Cholangiocarcinoma: current concepts and insights. Hepatology 2003; 37: 9619.
  • 43
    Sirica AE . Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005; 41: 515.
  • 44
    Ochel HJ , Eichhorn K , Gademann G . Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones. Cell Stress Chaperones 2001; 6: 10512.
  • 45
    Maloney A , Workman P . HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002; 2: 324.
  • 46
    Gooljarsingh LT , Fernandes C , Yan K et al. A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proc Natl Acad Sci USA 2006; 103: 762530.